General Information of the Drug (ID: M6APDG04004)
Name
SL-172154
Status
Phase 1
TTD Drug ID
DKUF26
Target Gene(s) and Their Upstream m6A Regulator, Together with the Effect of Target Gene(s) in Drug Response
The target genes involved in drug-target interaction (such as drug-metabolizing enzymes, drug transporters and therapeutic targets) and drug-mediated cell death signaling (including modulating DNA damage and repair capacity, escaping from drug-induced apoptosis, autophagy, cellular metabolic reprogramming, oncogenic bypass signaling, cell microenvironment, cell stemness, etc.) could be regulated by m6A regulator(s) and affected their corresponding drug response. You can browse detailed information on drug-related target gene(s) mediated by m6A regulators.
Leukocyte surface antigen CD47 (CD47)
Insulin-like growth factor 2 mRNA-binding protein 1 (IGF2BP1)
In total 1 mechanisms lead to this potential drug response
Response Summary Leukocyte surface antigen CD47 (CD47) is a therapeutic target for SL-172154. The Insulin-like growth factor 2 mRNA-binding protein 1 (IGF2BP1) has potential in affecting the response of SL-172154 through regulating the expression of Leukocyte surface antigen CD47 (CD47). [1], [2]
Methyltransferase-like 3 (METTL3)
In total 1 mechanisms lead to this potential drug response
Response Summary Leukocyte surface antigen CD47 (CD47) is a therapeutic target for SL-172154. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of SL-172154 through regulating the expression of Leukocyte surface antigen CD47 (CD47). [1], [2]
References
Ref 1 METTL3/IGF2BP1/CD47 contributes to the sublethal heat treatment induced mesenchymal transition in HCC. Biochem Biophys Res Commun. 2021 Mar 26;546:169-177. doi: 10.1016/j.bbrc.2021.01.085. Epub 2021 Feb 12.
Ref 2 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)